Compare PEN & ALLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEN | ALLY |
|---|---|---|
| Founded | 2004 | 1919 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 12.3B |
| IPO Year | 2015 | 2011 |
| Metric | PEN | ALLY |
|---|---|---|
| Price | $324.37 | $43.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 13 |
| Target Price | ★ $360.14 | $54.42 |
| AVG Volume (30 Days) | 496.9K | ★ 3.3M |
| Earning Date | 04-30-2026 | 04-17-2026 |
| Dividend Yield | N/A | ★ 2.70% |
| EPS Growth | ★ 1155.56 | 31.67 |
| EPS | ★ 4.52 | 2.37 |
| Revenue | $1,403,665,000.00 | ★ $7,914,000,000.00 |
| Revenue This Year | $14.34 | $24.30 |
| Revenue Next Year | $13.71 | $4.31 |
| P/E Ratio | $72.18 | ★ $18.70 |
| Revenue Growth | ★ 17.50 | N/A |
| 52 Week Low | $221.26 | $32.07 |
| 52 Week High | $362.41 | $47.27 |
| Indicator | PEN | ALLY |
|---|---|---|
| Relative Strength Index (RSI) | 35.74 | 57.70 |
| Support Level | $302.19 | $37.23 |
| Resistance Level | $337.50 | $46.83 |
| Average True Range (ATR) | 2.80 | 1.18 |
| MACD | -0.32 | 0.00 |
| Stochastic Oscillator | 8.78 | 48.22 |
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending, with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.